![](/images/smile/19.jpg)
![](/images/smile/257.jpg)
![](/images/smile/113.jpg)
![](/images/smile/348.jpg)
![](/images/smile/58.jpg)
![](/images/smile/292.jpg)
![](/images/smile/16.jpg)
![](/images/smile/222.jpg)
![](/images/smile/168.jpg)
![](/images/smile/312.jpg)
![](/images/smile/142.jpg)
![](/images/smile/201.jpg)
![](/images/smile/17.jpg)
![](/images/smile/181.jpg)
![](/images/smile/112.jpg)
![](/images/smile/277.jpg)
![](/images/smile/59.jpg)
![](/images/smile/201.jpg)
![](/images/smile/163.jpg)
![](/images/smile/184.jpg)
![](/images/smile/134.jpg)
![](/images/smile/234.jpg)
![](/images/smile/92.jpg)
![](/images/smile/265.jpg)
Background and objective: Armodafinil, a non-amphetamine, wakefulness-promoting medication, is the R- and longer-lasting isomer of racemic modafinil. Armodafinil has been shown to improve wakefulness in patients with excessive sleepiness (ES) associated with treated obstructive sleep apnoea, shift work disorder or narcolepsy.
![](/images/whatsapp.png)
![](/images/smile/172.jpg)
![](/images/smile/231.jpg)
![](/images/smile/134.jpg)
![](/images/smile/253.jpg)
![](/images/smile/14.jpg)
![](/images/smile/231.jpg)
![](/images/smile/86.jpg)
![](/images/smile/318.jpg)
![](/images/smile/114.jpg)
![](/images/smile/183.jpg)
![](/images/smile/10.jpg)
![](/images/smile/190.jpg)
![](/images/smile/139.jpg)
![](/images/smile/302.jpg)
![](/images/smile/52.jpg)
![](/images/smile/215.jpg)
![](/images/smile/17.jpg)
![](/images/smile/189.jpg)
![](/images/smile/98.jpg)
![](/images/smile/300.jpg)
![](/images/smile/115.jpg)
![](/images/smile/230.jpg)
![](/images/smile/121.jpg)
![](/images/smile/265.jpg)
![](/images/smile/11.jpg)
![](/images/smile/204.jpg)
![](/images/smile/5.jpg)
![](/images/smile/191.jpg)
![](/images/smile/73.jpg)
![](/images/smile/321.jpg)
![](/images/smile/73.jpg)
![](/images/smile/247.jpg)
![](/images/smile/54.jpg)
![](/images/smile/184.jpg)
![](/images/smile/36.jpg)
![](/images/smile/342.jpg)